GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (FRA:6L8) » Definitions » Long-Term Capital Lease Obligation

Pulse Biosciences (FRA:6L8) Long-Term Capital Lease Obligation : €7.17 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Pulse Biosciences Long-Term Capital Lease Obligation?

Pulse Biosciences's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €7.17 Mil.

Pulse Biosciences's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€7.84 Mil) to Dec. 2023 (€7.42 Mil) and declined from Dec. 2023 (€7.42 Mil) to Mar. 2024 (€7.17 Mil).

Pulse Biosciences's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€8.89 Mil) to Dec. 2022 (€8.63 Mil) and declined from Dec. 2022 (€8.63 Mil) to Dec. 2023 (€7.42 Mil).


Pulse Biosciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Pulse Biosciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Long-Term Capital Lease Obligation Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.05 8.89 8.89 8.63 7.42

Pulse Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.31 7.98 7.84 7.42 7.17

Pulse Biosciences  (FRA:6L8) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Pulse Biosciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (FRA:6L8) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Pulse Biosciences (FRA:6L8) Headlines

No Headlines